Ghaziabad Online

Pancreatic Ductal Adenocarcinoma Pipeline Appears Robust With 80+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

 Breaking News
  • No posts were found

Pancreatic Ductal Adenocarcinoma Pipeline Appears Robust With 80+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

January 23
19:07 2023

DelveInsight’s, “Pancreatic Ductal Adenocarcinoma Pipeline Insight, 2022,” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Pancreatic Ductal Adenocarcinoma pipeline landscape. It covers the Pancreatic Ductal Adenocarcinoma pipeline drug profiles, including Pancreatic Ductal Adenocarcinoma clinical trials and nonclinical stage products. It also covers the Pancreatic Ductal Adenocarcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

In the Pancreatic Ductal Adenocarcinoma Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, Pancreatic Ductal Adenocarcinoma clinical trial studies, Pancreatic Ductal Adenocarcinoma NDA approvals (if any), and product development activities comprising the technology, Pancreatic Ductal Adenocarcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Key takeaways from the Pancreatic Ductal Adenocarcinoma Pipeline Report

  • DelveInsight’s Pancreatic Ductal Adenocarcinoma Pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Pancreatic Ductal Adenocarcinoma.
  • The leading Pancreatic Ductal Adenocarcinoma Companies such as Alligator Bioscience, Cardiff Oncology, Novartis, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Cantargia AB, Nelum Corp, GC Cell Corporation, OSE Immunotherapeutics, Eucure (Beijing) Biopharma Co., Ltd, Panbela Therapeutics, Inc., Onconic Therapeutics Inc., Elicio Therapeutics, Cend Therapeutics, Silenseed Ltd, Amplia Therapeutics Limited, Bristol-Myers Squibb, Revolution Medicines, Inc., Taiho Pharmaceutical, Genmab, Deciphera Pharmaceuticals LLC, NGM Biopharmaceuticals, Multitude Therapeutics, Seagen Inc., Tarveda Therapeutics, I-Mab Biopharma Co. Ltd., Incyte Corporation, ZielBio, Inc., DrugCendR Inc., Bayer, TriSalus Life Sciences, Jacobio Pharma, BioLineRx Ltd., Purple Biotech Ltd., Biomea Fusion, Inc., Phanes Therapeutics, Qualigen Therapeutics, and others are evaluating new drugs for pancreatic ductal adenocarcinoma to improve the treatment landscape.
  • Promising pancreatic ductal adenocarcinoma pipeline therapies in various stages of development include Mitazalimab, Onvansertib, NIS793, KN046,  CAN04, NLM-001, Immuncell-LC, OSE2101, YH003, SBP-101, JPI-547, ELI-002, CEND-1, siG12D-LODER, AMP945, BMS-813160, CAN04, RMC-6236, AB122, GEN1042, DCC-3116, NGM707, AMT-151, SGN-CD228A, PEN-866, TJ033721, INCB106385, ZB131, BR55, CEND-1, BAY2287411, SD-101, JAB-21822, CM24, and others.
  • The Pancreatic Ductal Adenocarcinoma Companies and academics are working to assess challenges and seek opportunities that could influence R&D Pancreatic Ductal Adenocarcinoma. The Pancreatic Ductal Adenocarcinoma pipeline therapies under development are focused on novel approaches to treat/improve Pancreatic Ductal Adenocarcinoma.

 

To explore more information on the latest breakthroughs in the Pancreatic Ductal Adenocarcinoma Pipeline treatment landscape of the report, click here @ Pancreatic Ductal Adenocarcinoma Pipeline Outlook

 

Recent Developmental Activities in the Pancreatic Ductal Adenocarcinoma Treatment Landscape

  • In July 2022, Cend Therapeutics, Inc. announced that The Lancet Gastroenterology and Hepatology published data from the Phase 1b study of CEND-1, Cend’s lead investigational drug, in combination with gemcitabine and nab-paclitaxel for the treatment of first-line, metastatic pancreatic ductal adenocarcinoma (“mPDAC”).
  • In July 2022, I-Mab announced that the first patient in China has been treated with TJ-CD4B (also known as ABL111), a novel Claudin 18.2 x 4-1BB bispecific antibody, in a Phase 1 international multi-center clinical trial (IMCT) for patients with solid tumors, including gastric cancer, gastroesophageal junction carcinoma, esophageal adenocarcinoma, and pancreatic ductal carcinoma.
  • In June 2022, BioNTech SE announced initial data from an ongoing investigator-initiated first-in-human Phase 1 study evaluating the safety and tolerability of the mRNA-based individualized neoantigen-specific immunotherapy (iNeST) autogene cevumeran (also known as BNT122, RO7198457) in combination with anti-PD-L1 immune checkpoint inhibitor atezolizumab and chemotherapy in patients with resected pancreatic ductal adenocarcinoma (PDAC). Feasibility of the process of profiling each patient’s tumor to inform individualized vaccine design and on-demand manufacturing of iNeST in a clinically relevant timeframe was confirmed. The preliminary results showed a favorable safety profile as well as encouraging signs of clinical activity.
  • In June 2022, BioLineRx Ltd. announced that the Company had entered into a collaboration agreement with GenFleet Therapeutics, an immuno-oncology-focused biopharmaceutical company based in China, to advance Motixafortide through a randomized Phase 2b clinical trial in pancreatic ductal adenocarcinoma, or PDAC.
  • In May 2022, Elicio Therapeutics, announced that it had entered into a clinical supply agreement with Regeneron to evaluate the safety and efficacy of Elicio’s lead asset, ELI-002, an investigational KRAS-targeted cancer vaccine, in combination with Regeneron’s Libtayo® (cemiplimab), a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T cells, in patients with KRAS-driven tumors. The combination therapy will be studied in KRAS-driven tumors, including Stage III and IV non-small cell lung cancer (NSCLC), Stage IV colorectal cancer (CRC), and unresectable, locally advanced, or oligometastatic pancreatic ductal adenocarcinoma (PDAC).
  • In May 2022, OSE Immunotherapeutics SA and its clinical partners GERCOR, ARCAGY-GINECO, and the FoRT Foundation (Fondazione Ricerca Traslazionale), announced four poster presentations featuring neoepitope combination Tedopi® in various cancer indications at the American Society of Clinical Oncology (ASCO) Annual Meeting that was held from June 4 – 7, 2022 in Chicago. The first poster was titled, “A randomized non-comparative phase II study of maintenance OSE2101 vaccine alone or in combination with nivolumab (nivo), or FOLFIRI after induction with FOLFIRINOX in patients (Pts) with advanced pancreatic ductal adenocarcinoma (aPDAC): first interim results of the TEDOPAM GERCOR D17-01 PRODIGE 63 STUDY”.
  • In May 2022, Purple Biotech Ltd. announced the initiation of the Phase 2 portion of its ongoing study of CM24, a first-in-class monoclonal antibody with the potential to treat multiple cancers. Phase 2 is an open-label, multicenter study in subjects with metastatic pancreatic cancer (PDAC) to evaluate the safety and tolerability of CM24 in combination with the PD-1 inhibitor Opdivo® (nivolumab) and chemotherapy. The primary study endpoint is to evaluate preliminary efficacy in 2nd line PDAC.
  • In March 2022, Alligator Bioscience announced an update on the ongoing OPTIMIZE-1 clinical Phase Ib/II trial in first-line metastatic pancreatic cancer with the company’s lead asset, mitazalimab. Safety evaluation of the second dose-escalation cohort (900 µg/kg of mitazalimab in combination with mFOLFIRINOX) has concluded, which marks the successful completion of the Phase Ib part of the study. The Data Review Committee had declared the 900 µg/kg mitazalimab dose to be safe and recommended that the dosing level should be continued for the Phase II study. Enrollment for Phase II has begun and is ongoing at sites in Europe. OPTIMIZE-1, an open-label, multi-center Phase Ib/II study is assessing the safety and efficacy of mitazalimab in combination with chemotherapy, mFOLFIRINOX, in patients with metastatic pancreatic ductal adenocarcinoma.

 

Pancreatic Ductal Adenocarcinoma Overview

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal diseases, with an average 5-year survival rate of less than 10%. Unfortunately, the majority of patients have unresectable, locally advanced, or metastatic disease at the time of diagnosis. PDAC development is associated with a poor prognosis due to its complicated and multifactorial nature. There is a lack of simple, early detection methods and is typically diagnosed at a late stage because symptoms do not appear until the disease has progressed and metastasized to distinct sites. The major difficulties in treating pancreatic cancer lie at both the genetic and cellular levels. The extent of mutational changes in pancreatic tumors generates gene instability that appears to play an essential role in PDAC tumor growth and resistance to treatments.

 

Request a sample and discover the recent advances in Pancreatic Ductal Adenocarcinoma Ongoing Clinical Trial Analysis and Medications, click here @ Pancreatic Ductal Adenocarcinoma Treatment Landscape

 

Pancreatic Ductal Adenocarcinoma Emerging Drugs Profile

 

Onvansertib: Cardiff Oncology

Onvansertib, an oral highly-selective PLK1 inhibitor, which we are evaluating in combination with standard-of-care (SOC) therapeutics in clinical programs targeting indications such as KRAS-mutated metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, and metastatic castrate-resistant prostate cancer. These programs and our broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SOC.

 

Nadunolimab: Cantargia

Nadunolimab is a humanised monoclonal antibody lacking fucose, being developed by Cantargia, for the treatment of solid tumours, including non-small cell lung cancer (NSCLC) and pancreatic cancer. Nadunolimab is a first-in-class anti-IL1RAP antibody, currently evaluated with standard of care chemotherapy or checkpoint inhibitor in five phase I/II clinical trials with a primary focus on PDAC and NSCLC. Nadunolimab induces ADCC and blocks signaling of both IL-1α and IL-1β, counteracting thecontribution of IL-1 to the immune suppressive tumor microenvironment and development of resistance to chemotherapy

 

Zimberelimab: Arcus Biosciences

Zimberelimab is a monoclonal antibody that binds pd-1 restoring the antitumor activity of T-cells. Zimberelimab was in-licensed by Arcus to enable the development of precision combination regimens with The most advanced study with zimberelimab is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer, evaluating zimberelimab in combination with domvanalimab, an anti-TIGIT monoclonal antibody, and etrumadenant, the first and only dual A2a/A2b adenosine receptor antagonist in the clinic. Zimberelimab is also being evaluated as monotherapy in a tumor agnostic, biomarker-selected Phase 1b trial for cancers with no approved anti-PD-1 treatment options. full line-of-sight to the commercialization of innovative therapies for all patients who may benefit.

 

Pancreatic Ductal Adenocarcinoma Pipeline Therapeutic Assessment

 

There are approx. 80+ key companies which are developing the therapies Pancreatic Ductal Adenocarcinoma. The Pancreatic Ductal Adenocarcinoma companies which have their Pancreatic Ductal Adenocarcinoma drug candidates in the most advanced stage, i.e phase III include XOMA.

 

For further information, refer to the detailed Pancreatic Ductal Adenocarcinoma Unmet Needs, O Pancreatic Ductal Adenocarcinoma Market Drivers, and Market Barriers, click here for Pancreatic Ductal Adenocarcinoma Ongoing Clinical Trial Analysis

 

Scope of the Pancreatic Ductal Adenocarcinoma Pipeline Report

 

  • Coverage- Global
  • Pancreatic Ductal Adenocarcinoma CompaniesAlligator Bioscience, Cardiff Oncology, Novartis, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Cantargia AB, Nelum Corp, GC Cell Corporation, OSE Immunotherapeutics, Eucure (Beijing) Biopharma Co., Ltd, Panbela Therapeutics, Inc., Onconic Therapeutics Inc., Elicio Therapeutics, Cend Therapeutics, Silenseed Ltd, Amplia Therapeutics Limited, Bristol-Myers Squibb, Revolution Medicines, Inc., Taiho Pharmaceutical, Genmab, Deciphera Pharmaceuticals LLC, NGM Biopharmaceuticals, Multitude Therapeutics, Seagen Inc., Tarveda Therapeutics, I-Mab Biopharma Co. Ltd., Incyte Corporation, ZielBio, Inc., DrugCendR Inc., Bayer, TriSalus Life Sciences, Jacobio Pharma, BioLineRx Ltd., Purple Biotech Ltd., Biomea Fusion, Inc., Phanes Therapeutics, Qualigen Therapeutics, and others.
  • Pancreatic Ductal Adenocarcinoma Pipeline Therapies- Mitazalimab, Onvansertib, NIS793, KN046,  CAN04, NLM-001, Immuncell-LC, OSE2101, YH003, SBP-101, JPI-547, ELI-002, CEND-1, siG12D-LODER, AMP945, BMS-813160, CAN04, RMC-6236, AB122, GEN1042, DCC-3116, NGM707, AMT-151, SGN-CD228A, PEN-866, TJ033721, INCB106385, ZB131, BR55, CEND-1, BAY2287411, SD-101, JAB-21822, CM24, and others.
  • Pancreatic Ductal Adenocarcinoma Pipeline Segmentation: Phases, Product Type, Molecule Type, Route of administration, Mechanism of Action

 

Dive deep into rich insights for drugs for Pancreatic Ductal Adenocarcinoma Market Drivers and Pancreatic Ductal Adenocarcinoma Market Barriers, click here @ Pancreatic Ductal Adenocarcinoma Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Pancreatic Ductal Adenocarcinoma Executive Summary
  3. Pancreatic Ductal Adenocarcinoma: Overview
  4. Pancreatic Ductal Adenocarcinoma Pipeline Therapeutics
  5. Pancreatic Ductal Adenocarcinoma Therapeutic Assessment
  6. Pancreatic Ductal Adenocarcinoma– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. NIS 793: XOMA
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. CEND 1: Cend Therapeutics
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. DCC-3116: Deciphera Pharmaceuticals
  15. Drug profiles in the detailed report…..
  16. Early Stage Products (Phase I)
  17. RMC-6236: REVOLUTION Medicines
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Pancreatic Ductal Adenocarcinoma Key Companies
  21. Pancreatic Ductal Adenocarcinoma Key Products
  22. Pancreatic Ductal Adenocarcinoma- Unmet Needs
  23. Pancreatic Ductal Adenocarcinoma- Market Drivers and Barriers
  24. Pancreatic Ductal Adenocarcinoma- Future Perspectives and Conclusion
  25. Pancreatic Ductal Adenocarcinoma Analyst Views
  26. Pancreatic Ductal Adenocarcinoma Key Companies
  27. Appendix

 

Got Queries? Find out the related information on Pancreatic Ductal Adenocarcinoma Mergers and acquisitions, Pancreatic Ductal Adenocarcinoma licensing activities @ Pancreatic Ductal Adenocarcinoma Emerging Drugs, and Recent Trends

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Categories